Regeneron RUBY DME-1518

Status: Ongoing, but not recruiting participants

ClinicalTrials.gov Identifier: NCT02712008

Regeneron Ruby: A randomized, double-masked active-controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of repeated doses of Intravitreal REGN910-3 in patients DME.

Condition: Diabetic Macular Edema

Study Type: Interventional

Duration: 36 weeks

Eligibility: 

  • Ages: 18 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.